A prospective multicenter study found improvements in ocular surface integrity, tear-film stability, tear production, and symptom burden over 60 days in patients with moderate-to-severe dry eye disease.
A 20-week INSIGHT extension suggests that switching from reference aflibercept to MYL-1701P maintained comparable safety, visual, and anatomic outcomes in patients with diabetic macular edema.
A nationwide Swedish cohort found a higher relative risk of anterior ischemic optic neuropathy among GLP-1 receptor agonist users, but the overall risks were low.
From breathier speech to breastfeeding history, metamaterial eye coils, and antifibrotic GLP-1 effects in mice, this week’s studies remind us that the most interesting signal is often hiding somewhere clinicians were not looking.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.
Nearly 10 years of observational follow-up suggested sustained axial-length slowing, although refractive findings were less consistent and comparisons relied on statistical modeling.